

COVID ROOC
More Information Bank
TOPIC CHOICES

Note: Not all sources are peer-reviewed whereas some are reviews and interesting blogs. They are not intended in themselves to guide patient management decisions.

Reviews of COVID-19 and Autoinflammatory Diseases

[Autoimmune and autoinflammatory conditions after COVID-19 vaccination. New case reports and updated literature review \(August, 2022\)](#)

[Cutaneous symptoms of connective tissue diseases after COVID-19 vaccination: a systematic review \(May, 2022\)](#)

[COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations \(April, 2022\)](#)

[Prevalence and risk of COVID-19 in patients with rheumatic diseases: a systematic review and meta-analysis \(March, 2022\)](#)

[Study: COVID-19 Vaccinations Are Safe for Patients with Lupus. \(April, 2022\)](#)

[Clinical practice guidelines in multisystem inflammatory syndrome \(MIS-C\) related to COVID-19: a critical review and recommendations. \(January, 2022\)](#)

[SARS-CoV-2 outbreak in immune-mediated inflammatory diseases: the Euro-COVIMID multicentre cross-sectional study \(July, 2021\)](#)

[COVID-19 in patients with rheumatic disease: finally, a denominator \(July, 2021\)](#)

[Autoimmune and Rheumatic Manifestations Associated With COVID-19 in Adults: An Updated Systematic Review \(March, 2021\)](#)

[COVID-19 in early 2021: current status and looking forward \(March, 2021\)](#)

[The Pathogenesis and Treatment of COVID-19: A System Review \(February, 2021\)](#)

[COVID-19: molecular pathophysiology, genetic evolution and prospective therapeutics— a review \(February, 2021\)](#)

[Rheumatic disease and COVID-19: epidemiology and outcomes \(December, 2020\)](#)

COVID-19 Testing

[COVID-19 testing policies. Sep, 2022](#)

[Discrimination of COVID-19 From Inflammation-Induced Cytokine Storm Syndromes Using Disease-Related Blood Biomarkers. \(October, 2021\)](#)

[Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. \(July, 2021\)](#)

[Abbott's COVID-19 Rapid Antigen Test Authorized for OTC Serial Asymptomatic Testing \(April, 2021\)](#)

[Coronavirus \(COVID-19\) Update \(April, 2021\)](#)

[From labs to homes: where COVID-19 testing is headed in 2021 \(March, 2021\)](#)

Risk Factors for Patients with Rheumatic Diseases and COVID-19

[Risk factors for hospitalization or mortality for COVID-19 in patients with rheumatic diseases: Results of a nation-wide JCR COVID-19 registry in Japan. \(September, 2022\)](#)

[Autoimmune Inflammatory Disease Increases Risk of COVID-19 Hospitalization. \(July, 2022\)](#)

[Risk Factors for Infection, Predictors of Severe Disease, and Antibody Response to COVID-19 in Patients with Inflammatory Rheumatic Diseases in Portugal—A Multicenter, Nationwide Study. \(June, 2022\)](#)

[COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations. \(February, 2022\)](#)

[More Than 28 Million Excess Years of Life Lost During Pandemic. \(November, 2021\)](#)

[Risk of Severe COVID-19 Infection in Patients with Inflammatory Rheumatic Diseases. \(July, 2021\)](#)

[Laboratory trends, hyperinflammation, and clinical outcomes for patients with a systemic rheumatic disease admitted to hospital for COVID-19: a retrospective, comparative cohort study. \(May, 2021\)](#)

[Variables Associated with Perceived Risk of Contracting SARS-CoV-2 Infection During the COVID-19 Pandemic Among Patients with Systemic Rheumatic Diseases \(April, 2021\)](#)

[Risk factors for severe outcomes in patients with systemic vasculitis & COVID-19: a bi-national registry-based cohort study \(March, 2021\)](#)

[Risk factors for COVID-19 and rheumatic disease flare in a US cohort of Latino patients \(January, 2021\)](#)

[Non-steroidal anti-inflammatory drugs and susceptibility to COVID-19 \(November, 2020\)](#)

[Susceptibility to COVID-19 in Patients Treated with Antimalarials: A Population-Based Study in Emilia-Romagna, Northern Italy \(August, 2020\)](#)

[Synergy Between Cytokines and Risk Factors in the Cytokine Storm of COVID-19: Does Ongoing Use of Cytokine Inhibitors Have a Protective Effect? \(July, 2020\)](#)

[Anticardiolipin IgG Autoantibody Level Is an Independent Risk Factor for COVID-19 Severity \(June, 2020\)](#)

[Association of Race and Ethnicity With COVID-19 Outcomes in Rheumatic Disease: Data From the COVID-19 Global Rheumatology Alliance Physician Registry \(November, 2020\)](#)

RA, PsA, SLE & other Rheumatic Diseases Associated with COVID-19

[Clinical characteristics of COVID-19 patients with underlying rheumatic diseases in Japan: data from a multicenter observational study using the COVID-19 Global Rheumatology Alliance physician-reported registry. \(August, 2022\)](#)

[SARS-CoV-2 triggering autoimmune diseases. \(June, 2022\)](#)

[Different Covid-19 Outcomes Among Systemic Rheumatic Diseases: A Nation-wide Cohort Study. \(March, 2022\)](#)

[Prevalence of symptoms more than seven months after diagnosis of symptomatic COVID-19 in an outpatient setting \(October, 2021\).](#)

[Tracking SARS-CoV-2 variants. \(August, 2021\)](#)

[Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the international VACOLUP study. \(July, 2021\)](#)

[Non-steroidal anti-inflammatory drug use in COVID-19 \(July, 2021\)](#)

[New COVID-19 projections. Insights from IHME's latest COVID-19 model update.](#)

[Risk of Severe COVID-19 Infection in Patients with Inflammatory Rheumatic Diseases. \(July, 2021\)](#)

[Effect of the COVID-19 pandemic on patients with systemic rheumatic diseases. \(July, 2021\)](#)

[Incident systemic rheumatic disease following COVID-19 \(June, 2021\).](#)

[NIH scientists say they may have found a promising new oral antiviral drug for Covid \(June, 2021\)](#)

[Covid News: W.H.O. Notes Sharp Drop in New Cases in Europe Over Past Month \(May, 2021\)](#)

[Evaluation of SARS CoV-2 IgG antibody reactivity in patients with systemic lupus erythematosus: analysis of multi-racial and multi-ethnic cohort. \(May, 2021\).](#)

[Dermatology COVID-19 Registries: Updates and Future Directions. \(May, 2021\)](#)

[Association of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry. \(May, 2021\)](#)

[Does withdrawal of immunosuppression in rheumatoid arthritis after SARS-CoV infection increase the risk of vasculitis \(April, 2021\)](#)

[The Psychological Functioning in the COVID-19 Pandemic and Its Association with Psychological Flexibility and Broader Functioning in People With Chronic Pain. \(March, 2021\)](#)

[COVID-19 and systemic sclerosis: clinicopathological implications from Italian nationwide survey study. \(March, 2021\)](#)

[Review: COVID-19 Vasculitis or Novel Vasculitis Mimic? \(February, 2021\)](#)
[Managing patients with rheumatic diseases treated with rituximab during the COVID-19 pandemic \(June, 2021\)](#)

[Weathering the Storm: Immunomodulators in the Management of COVID-19 \(May, 2021\)](#)

[Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. \(May, 2021\)](#)

[Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2. \(April, 2021\)](#)

[Clinical Trial Tests Efficacy of Anti-Inflammatory Drug to Treat People with COVID-19 \(April, 2021\)](#)

[Clinical outcomes of COVID-19 in patients with rheumatic diseases: A systematic review and meta-analysis of global data. \(April, 2021\)](#)

[Colchicine | COVID-19 Treatment Guidelines \(CDC\) \(April, 2021\)](#)

[Anti-inflammatory therapy for COVID-19 infection: the case for colchicine \(2021\)](#)

[Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2 \(April, 2021\)](#)

[The relationship between cultural tightness-looseness and COVID-19 cases and deaths: a global analysis. \(January, 2021\)](#)

[Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study. \(January, 2021\)](#)

[COVID-19 in patients with systemic lupus erythematosus: lessons learned from the inflammatory disease \(December, 2020\)](#)

Prognosis, Outcomes, Long Haulers, and Mortality in COVID-19 with Rheumatic Diseases

[COVID-19 in patients with rheumatic diseases: what is the real mortality risk? \(August, 2022\)](#)

[DMARD disruption, rheumatic disease flare, and prolonged COVID-19 symptom duration after acute COVID-19 among patients with rheumatic disease: A prospective study. \(August, 2022\)](#)

[Frequency, characteristics and outcome of corona virus disease 2019 \(COVID-19\) infection in Iranian patients with rheumatic diseases \(June, 2022\)](#)

[Rheumatic Disease and Long-Haul COVID-19. \(May, 2022\)](#)

[More Evidence COVID 'Brain Fog' Is Biologically Based. \(April, 2022\)](#)

[Comparisons of Clinical Features and Outcomes of COVID-19 between Patients with Pediatric Onset Inflammatory Rheumatic Diseases and Healthy Children. \(April, 2022\)](#)

[Multiple early factors anticipate post-acute COVID-19 sequelae. \(March, 2022\)](#)

[COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations. \(February, 2022\)](#)

[Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. \(February, 2022\)](#)

[Clinical outcomes of COVID-19 patients with rheumatic diseases: a retrospective cohort study and synthesis analysis in Wuhan, China. \(February, 2022\)](#)

[These 4 risk factors may increase your chance of long COVID, study hints. \(February, 2022\)](#)

[Clinical outcomes of breakthrough COVID-19 after booster vaccination in patients with systemic rheumatic diseases. \(February, 2022\)](#)

[Screening for SARS-CoV-2 persistence in Long COVID patients using sniffer dogs and scents from axillary sweats samples. \(January, 2022\)](#)

[COVID-19: Antibody “signature” could predict risk of long COVID. \(January, 2022\)](#)

[More Than Half of Patients with Rheumatic Diseases and COVID-19 Experience “Long-Haul” Symptoms. \(December, 2021\)](#)

[Growing Public Health Concern of COVID-19 Chronic Olfactory Dysfunction. \(November, 2021\)](#)

[Long COVID from rheumatology perspective — a narrative review. \(November, 2021\)](#)

[Use Of Rituximab, Jak Inhibitors at Time of Covid-19 Onset Increases Poor Outcomes. \(November, 2021\)](#)

[Autoimmune inflammatory rheumatic diseases and COVID-19 outcomes in South Korea: a nationwide cohort study \(June, 2021\)](#)

[COVID-19 Mortality is Associated with Impaired Innate Immunity in Pre-existing Health Conditions \(May, 2021\)](#)

[Clinical outcomes of COVID-19 in patients with rheumatic diseases: A systematic review and meta-analysis of global data \(April, 2021\)](#)

[Disease activity linked to COVID-19 mortality risk in rheumatology patients \(April, 2021\)](#)

[COVID Death: Which Rheumatic Patients Are at Risk? \(March, 2021\)](#)

[COVID-19-related death in rheumatic diseases. \(February, 2021\)](#)

[Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry \(January, 2021\)](#)

[COVID-19 and mortality in rare rheumatic diseases, a warning bell \(February, 2021\)](#)

[Increased Mortality Risk Among Patients with Rare Autoimmune Rheumatic Diseases During the COVID-19 Pandemic. \(January, 2021\)](#)

Sleep and Mental Disturbances During the COVID-19 Pandemic

[Patient-Reported Outcomes Positively Affected by Vaccine Availability During COVID-19 Pandemic. \(June, 2022\)](#)

[Psychological Stress Reported at the Start of the COVID-19 Pandemic and Subsequent Stress and Successful Coping in Patients With Rheumatic Diseases - A Longitudinal Analysis. \(April, 2022\)](#)

[Time to Sleep?—A Review of the Impact of the COVID-19 Pandemic on Sleep and Mental Health. \(March, 2022\)](#)

[Post-traumatic stress disorder in patients with rheumatic disease during the COVID-19 outbreak: a cross-sectional case–control study in China \(February, 2022\)](#)

[Prevalence of anxiety and depression in patients with rheumatoid arthritis before and during the COVID-19 pandemic. \(April, 2021\)](#)

[Could a good night's sleep improve COVID-19 vaccine efficacy? \(March, 2021\)](#)

[Mental health problems experienced by patients with rheumatic diseases during COVID-19 pandemic \(January, 2021\)](#)

[Putative contributions of circadian clock and sleep in the context of SARS-CoV-2 infection. \(January, 2021\)](#)

[The Role of Sleep in Patients with COVID-19 \(April, 2021\)](#)

[Increased risk of mental health disorders in patients with RA during the COVID-19 pandemic: a possible surge and solutions \(May, 2021\)](#)

[Psychological Distress in Patients with Autoimmune Arthritis during the COVID-19 Induced Lockdown in Italy \(November, 2020\)](#)

[Psychological State and Associated Factors During the 2019 Coronavirus Disease \(COVID-19\) Pandemic Among Filipinos with Rheumatoid Arthritis or Systemic Lupus Erythematosus. \(September, 2020\)](#)

[Pain-related diseases and sleep disorders \(August, 2012\)](#)

Prevention and Treatment of Rheumatic Diseases with COVID-19

[COVID-19: Management of adults with acute illness in the outpatient setting. \(August, 2022\) UpToDate](#)

[Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: from the first wave through the initial Omicron wave. \(July, 2022\)](#)

[Paxlovid Mouth Is Real—And Gross. \(May, 2022\)](#)

[Medication Interruptions and Subsequent Disease Flares During the COVID-19 Pandemic: A Longitudinal Online Study of Patients With Rheumatic Disease. \(May, 2021\)](#)

[Fact Sheet for Patients, Parents And Caregivers Emergency Use Authorization \(EUA\) of EVUSHELD \(tixagevimab co-packaged with cilgavimab\) for Coronavirus Disease 2019 COVID-19\) \(May, 2022\)](#)

[Monoclonal Antibody, Antiviral Therapies Struggle to Keep Pace with COVID-19 Variants. \(April 2022\)](#)

[Telemedicine in the Management of Patients with Rheumatic Disease during COVID-19 Pandemic: Incidence of Psychiatric Disorders and Fibromyalgia in Patients with Rheumatoid Arthritis and Psoriatic Arthritis. \(March, 2022\)](#)

[Safety and efficacy of colchicine in COVID-19 patients: A systematic review and meta-analysis of randomized control trials. \(April, 2022\)](#)

[COVID-19: Care of adult patients with systemic rheumatic disease. \(April, 2022\)](#)

[Ritonavir -Boosted Nirmatrelvir \(Paxlovid\). \(February, 2022\)](#)

[Colchicine Against SARS-CoV-2 Infection: What is the Evidence? \(February, 2022\)](#)

[Efficacy and safety of three new oral antiviral treatment \(molnupiravir, fluvoxamine and Paxlovid\) for COVID-19 : a meta-analysis. \(February, 2022\)](#)

[Paxlovid for treatment of COVID-19. \(January, 2022\)](#)

[Registry data reveal safety of COVID-19 vaccines in people with rheumatic and musculoskeletal diseases. \(January, 2022\)](#)

[Who, what, and when—effective therapy for severe COVID-19. \(November, 2021\)](#)

[Use of rituximab, JAK inhibitors at time of COVID-19 onset increases poor outcomes. \(November, 2021\)](#)

[Antibody cocktail reduces chance of developing COVID. \(October, 2021\)](#)

[A role for interleukin-1 receptor antagonism in severe COVID-19. \(October, 2021\)](#)

[Merck's new COVID-19 pill: 'Game changer' or just one more tool? \(October, 2021\)](#)

[Managing Rheumatoid Arthritis in the COVID-19 Era. \(September, 2021\)](#)

[Managing patients with rheumatic diseases treated with rituximab during the COVID-19 pandemic \(June, 2021\)](#)

[Weathering the Storm: Immunomodulators in the Management of COVID-19 \(May, 2021\)](#)

[Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry. \(May, 2021\)](#)

[Disruptions in Rheumatology Care and the Rise of Telehealth in Response to the COVID-19 Pandemic in a Community Practice–Based Network. May, 2021\)](#)

[Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2. \(April, 2021\)](#)

[Clinical Trial Tests Efficacy of Anti-Inflammatory Drug to Treat People with COVID-19. \(April, 2021\)](#)

[Colchicine | COVID-19 Treatment Guidelines \(CDC\) \(April, 2021\)](#)

[Anti-inflammatory therapy for COVID-19 infection: the case for colchicine \(2021\)](#)

[Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2 \(April, 2021\)](#)

[Study suggests high vitamin D levels may protect against COVID-19, especially for Black people. \(March, 2021\)](#)

[Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines. \(March, 2021\)](#)

Complications of Rheumatic Diseases with COVID-19

[Comparisons of Clinical Features and Outcomes of COVID-19 between Patients with Pediatric Onset Inflammatory Rheumatic Diseases and Healthy Children. \(April, 2022\)](#)

[COVID-19 in Patients With Rheumatic Diseases. Is There a Need to Worry? \(March, 2022\)](#)

[Exploring the attitudes, concerns, and knowledge regarding COVID-19 vaccine by the parents of children with rheumatic disease: Cross-sectional online survey. \(March, 2022\)](#)

[Early impacts of the COVID-19 pandemic on children with pediatric rheumatic diseases. \(January, 2022\)](#)

[Asymptomatic SARS-CoV-2 seropositivity: patients with childhood-onset rheumatic diseases versus healthy children. January, 2022\)](#)

[Discrimination of COVID-19 From Inflammation-Induced Cytokine Storm Syndromes Using Disease-Related Blood Biomarkers. \(October, 2021\)](#)

[Long-term Symptoms After SARS-CoV-2 Infection in Children and Adolescents. \(July, 2021\)](#)

[In for the long haul: Clinicians wrestle with post-acute COVID-19 syndromes. \(June, 2021\)](#)

[Long COVID in the skin: a registry analysis of COVID-19 dermatological duration. \(March, 2021\)](#)

[Cold and COVID: Recurrent Pernio during the COVID-19 Pandemic. \(March, 2021\)](#)

Children and Adolescents with Rheumatic Manifestations and COVID-19

[Post-COVID-19 Symptoms and Conditions Among Children and Adolescents — United States, March 1, 2020–January 31, 2022 \(August, 2022\)](#)

[COVID-19: Multisystem inflammatory syndrome in children \(MIS-C\) management and outcome. UpToDate \(August, 2022\)](#)

[Multisystem Inflammatory Syndrome and Autoimmune Diseases Following COVID-19: Molecular Mechanisms and Therapeutic Opportunities. \(April, 2022\)](#)

[Comparisons of Clinical Features and Outcomes of COVID-19 between Patients with Pediatric Onset Inflammatory Rheumatic Diseases and Healthy Children. \(April, 2022\)](#)

[Humoral response and safety of BNT162b2 mRNA vaccine in children with rheumatic diseases. \(March, 2022\)](#)

[Outcomes of SARS-CoV-2 infection among children and young people with pre-existing rheumatic and musculoskeletal diseases. \(March, 2022\)](#)

[Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in adolescents with rheumatic diseases treated with immunomodulatory medications. \(February, 2022\)](#)

[Still's Disease Following COVID-19 Vaccination. \(October, 2021\)](#)

[The clinical course of SARS-CoV-2 infection among children with rheumatic disease under biologic therapy: a retrospective and multicenter study. \(September, 2021\)](#)

[Presentation and Outcomes of Multisystem Inflammatory Syndrome in Children \(MIS-C\) Associated with COVID-19 in the Intermountain West. \(June, 2021\)](#)

[Severe COVID-19 in pediatric age: an update on the role of the anti-rheumatic agents. \(May, 2021\)](#)

[COVID-19 outcomes described in children with rheumatic diseases taking biologics. \(April, 2021\)](#)

[Cold and COVID: Recurrent Pernio during the COVID-19 Pandemic. \(March, 2021\)](#)

[SARS-CoV-2 infections in children and adolescents with rheumatic musculoskeletal diseases – data from the National Pediatric Rheumatology Database in Germany \(March, 2021\)](#)

[Psychosocial and clinical effects of the COVID-19 pandemic in patients with childhood rheumatic diseases and their parents. \(January, 2021\)](#)

Covid-19 in Rheumatic Diseases Miscellaneous

[Implications of SARS-CoV-2 infection for patients with rheumatic disease. \(August, 2022\)](#)

[Championing well-being amid COVID-19. \(March, 2022\)](#)

[Health Affairs study finds disparities in access to high-quality home health agencies. \(February, 2022\)](#)

